Zorbtive or serostim Market Report 2026

Zorbtive or serostim Market Overview

• The Zorbtive or serostim market growth in the historic period has been driven by increasing diagnosis of growth hormone deficiency, expansion of HIV-associated wasting treatment protocols • Market expansion is supported by increasing adoption of personalized hormone therapies, rising demand for improved quality-of-life treatments • Growth Driver: Rise In Number Of Patients With HIV Driving Market Growth Due To Increasing Demand For Growth Hormone Therapies In HIV Care • North America was the largest region in 2025.

What Is Covered Under Zorbtive or serostim Market?

Zorbtive or serostim are both recombinant human growth hormone therapies used to treat growth hormone deficiency, particularly in patients with conditions such as AIDS-related wasting or severe short stature. These treatments help stimulate growth, enhance protein synthesis, and improve overall body composition by increasing lean muscle mass and reducing fat. The main types of indications for zorbtive or serostim include short bowel syndrome and HIV-associated wasting. Short bowel syndrome (SBS) is a condition characterized by the body's inability to absorb sufficient nutrients due to a reduced functional small intestine. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used by adult and geriatric patients.

What Is The Zorbtive or serostim Market Growth Forecast?

The growth in the forecast period can be attributed to increasing adoption of personalized hormone therapies, rising demand for improved quality-of-life treatments, expansion of specialty pharmacy distribution, growing focus on long-acting formulations, increasing regulatory support for rare disease treatments. Major trends in the forecast period include increasing use of recombinant growth hormone therapies, rising focus on body composition improvement treatments, growing adoption of long-term hormone replacement regimens, expansion of specialized indication-based prescriptions, enhanced monitoring of therapy outcomes.

Global Zorbtive or serostim Market Segmentation

1) By Indication: Short Bowel Syndrome, HIV-Associated Wasting 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Zorbtive or serostim Market?

A rise in the number of patients with HIV is expected to propel the growth of the zorbtive or serostim market going forward. Human immunodeficiency virus (HIV) is a virus that weakens the immune system by targeting and destroying CD4 cells, which are essential for defending the body against infections. The rising prevalence of Human Immunodeficiency Virus (HIV) can be attributed to factors such as increased unprotected sexual activity, lack of access to preventative healthcare, insufficient awareness and education, and challenges in HIV testing and treatment, especially in certain high-risk populations. Zorbtive or serostim helps individuals with human immunodeficiency virus (HIV) by addressing HIV-associated wasting syndrome, promoting weight gain, increasing lean body mass, and improving overall physical function and quality of life for patients with compromised immune systems due to the virus. For instance, in October 2024, according to Health Security Agency (UKHSA), a US-based government agency, the number of newly diagnosed HIV cases in England rose by 15%, increasing from 2,451 in 2022 to 2,810 in 2023. Therefore, a rise in the number of patients with HIV is driving the growth of the zorbtive or serostim industry. The rising focus on personalized treatments is expected to propel the growth of the zorbtive or serostim market going forward. Personalized treatment is a medical approach that tailors therapy and care to an individual's unique genetic, environmental, and lifestyle factors to optimize outcomes. Personalized treatments are rising due to advancements in genetic research, improved diagnostic technologies, and a growing focus on more effective, targeted therapies that cater to individual patient needs. Zorbtive or serostim helps personalized treatments by targeting HIV-associated wasting syndrome, offering individualized therapy that promotes weight gain, increases lean body mass, and improves physical function, ultimately addressing the unique needs of patients with compromised immune systems due to HIV while enhancing their overall quality of life and treatment outcomes. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, In 2023, the US Food and Drug Administration (FDA) granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the six approvals in 2022. Therefore, the rising focus on personalized medicine is expected to drive the growth of the zorbtive or serostim industry. The growth in healthcare spending and investments is expected to propel the growth of the zorbtive or serostim market going forward. Healthcare spending and investment refer to the financial resources allocated by governments, private organizations, and individuals to support healthcare services, infrastructure, research, and innovation aimed at improving public health and medical outcomes. Healthcare spending and investments are rising due to factors such as an aging population, the increasing prevalence of chronic diseases, advancements in medical technology, and the growing demand for better healthcare services and treatments. Increasing healthcare spending supports the growth of the zorbtive or serostim market by funding research, improving access to treatment, and ensuring insurance coverage for patients with HIV-associated wasting syndrome, thereby enhancing treatment availability and affordability. For instance, in May 2024, according to the Office for National Statistics, a UK-based government agency, the UK’s total healthcare expenditure reached approximately $366 billion (£292 billion), reflecting a 5.6% increase in nominal terms. Of this, around $299 billion (£239 billion) was financed by the government. Therefore, the growth in healthcare spending and investments is driving the growth of the zorbtive or serostim industry.

Key Players In The Global Zorbtive or serostim Market

Major companies operating in the zorbtive or serostim market are EMD Serono Inc.

Regional Insights

North America was the largest region in the zorbtive or serostim market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Zorbtive or serostim Market?

The zorbtive or serostim market consists of sales of recombinant human growth hormone products, diagnostic kits, specialty medications, and nutritional and support products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Zorbtive or serostim Market Report 2026?

The zorbtive or serostim market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the zorbtive or serostim industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.